Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

istered as 30mg/m2 per day for five consecutive days then, based on their response, received up to five additional cycles of treatment at a dose of 20 mg/m2 per day for five consecutive days.

Significant Unmet Medical Need

The CLASSIC II study is designed to address a high unmet medical need among older AML patients who currently have limited treatment options. According to the American Cancer Society, each year approximately 6,500 people over the age of 60 are diagnosed with AML in the U.S. The median survival for those receiving therapy can vary from one to thirteen months, and the five-year survival rate over the past three decades remains at less than 10 to 15 percent. Older AML patients often have disease features such as unfavorable (adverse) cytogenetics and pre-existing blood disorders such as MDS that result in lower response rates and worse treatment outcomes to conventional induction chemotherapy compared with younger patients. In addition, conventional induction chemotherapy is poorly tolerated in older patients with unfavorable risk factors, and early induction mortality usually ranges from 10-30 percent but can exceed 30 percent in older patients with a poor performance status.

This study builds on promising results from two prior studies of single agent clofarabine in previously untreated older patients with AML deemed unfit for chemotherapy, based mostly on poor performance status and presence of co-morbid illnesses. These studies were conducted by Alan Burnett, M.D., of Cardiff University in the United Kingdom and presented at earlier American Society of Hematology meetings.

Clolar Clinical Development

A separate, phase 3 pivotal study (CLASSIC I) of clofarabine in relapsed adult AML patients aged 55 and older and previously treated with at least one, but not more than two, prior induction regimens is underway. This randomized, double-blind, placebo-controlled study will compare the combination of clofarabine and c
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Mass. , July 31, 2014  Decision Resources ... technology market intelligence product Marketrack to now include ChinaTrack; ... device landscape in an interactive dashboard providing detailed ... procedure volumes at a hospital level. Other ... , Updated data feed: In addition to end-user surveys ...
(Date:7/31/2014)... July 31, 2014 Lazarus Effect, a medical ... devices to facilitate removal of blood clots, announced the ... financing will support EU commercialization of several approved Lazarus ... Lazarus ReCover™ and Lazarus Cover™ in the ... investor confidence in the value of our novel, platform ...
(Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... WOONSOCKET, R.I. , Jan. 12 CVS Caremark Corporation (NYSE: ... increase in its quarterly dividend of approximately 15%, to 8.75 cents ... 2010 to holders of record on January 22, 2010 . This ... up 4.5 cents per share from the previous rate of ...
... , , BETHESDA, Md. , ... in biotechnology for diabetes therapy, and a provider of technical ... companies, today announced the completion of patient enrollment in its ... the safety and efficacy of D-tagatose as an oral treatment ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 2Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 3Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 4Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes 5
(Date:7/31/2014)... have developed a novel method for creating self-assembled ... in living cells. The work offers a promising ... and tissue engineering applications. The findings were published ... Chemie International Edition . , "We have demonstrated ... we can form completely new types of aggregates. ...
(Date:7/31/2014)... The International Bottled Water Association (IBWA) today launched a new ... Bottled Water – Always there when you need it ,” ... plays in times of natural disasters and other emergencies. , ... for hurricanes and other forms of severe weather, and this ... a moment to re-assess their risks and update hurricane kits ...
(Date:7/31/2014)... 31, 2014 ANS and Dr. Yaron Moshel ... ANS Skull Base Center and what the future holds for ... Base Surgery Center ?, Skull base surgery is a form ... the brain, an area historically considered very delicate and relatively ... areas was by retracting healthy brain tissue, leading to more ...
(Date:7/31/2014)... There,s sad news in the study of happiness. ... , University of Cincinnati research on perceived happiness shows ... coping. , This is despite the fact that there ... feel happier, says Keith King, professor and coordinator of ... they don,t use them enough. , "We have a ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... world’s first whirlpool bathtub, has launched a new and ... distributor customers alike. , The Jacuzzi Luxury Bath website ... mirrors the superior design and quality represented by the ... focus on product design and inspirational bathroom applications. “The ...
Breaking Medicine News(10 mins):Health News:Carnegie Mellon chemists create nanofibers using unprecedented new method 2Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 2Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 3Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 4Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 2Health News:Dr. Yaron Moshel of Atlantic NeuroSurgical Specialists (ANS) Discusses Brain Tumor Surgery 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2
... a new Medical,Industry Feature of the Week highlighting functional ... maintain healthy digestive flora.,This new programming will be sponsored ... the first and only network for medical professionals,will air ... twice a,day July 7-20. Healthcare professionals can tune in ...
... seeks policy, social changes that boost healthier eating, ... the high rate of obesity in the United States ... Heart Association (AHA) scientific statement. , The AHA also ... adopt healthy behaviors, such as eating right and being ...
... more effective than placebo, one expert says , , MONDAY, ... the pain of placing intravenous (IV) lines in children, ... reduced pain by 34 percent in children getting IV ... the success rate of inserting the lines, said lead ...
... percent of people worldwide suffer from migraines excruciating ... studying a rare, inherited form of migraine, researchers at ... biological basis of the painful, debilitating disorder. , In ... Alfred George Jr., M.D., and colleagues report that ...
... June 30 (HealthDay News) -- The risk of rheumatoid arthritis is ... (more than 10 pounds) than those with an average birth weight ... the Hospital for Special Surgery, New York City, analyzed data from ... Health Study between 1976 and 2002. The women were aged 30 ...
... researchers at the Ocean University of China has developed and ... can accurately measure wind speed and direction over large areas ... weather forecasting and sports. , As described in the ... published by the Optical Society, the mobile lidar station can ...
Cached Medicine News:Health News:ReachMD XM 157 Announces Medical Information Feature on Irritable Bowel Syndrome, Its Treatments, and the Role of Probiotics 2Health News:Population-Based Strategy Urged to Cut U.S. Obesity Rate 2Health News:Spray Cuts Kids' Pain When Getting IVs 2Health News:Migraine mutations reveal clues to biological basis of disorder 2Health News:New technology may help Olympic sailing 2
... Deviation Splint uses safe, mild to moderate ... deviation at the MP joints. Dorsal-based splint ... and ulnar polycentric hinges located at the ... Padded, malleable finger rings can be individually ...
... FREEDOM® Boxer Fracture Prefab Orthosis For ... fractures. Rigid Kydex shell immobilizes and ... T-Foam™ padded interior adds comfort, support, ... In hard-to-fit cases, the shell may ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
... makes dynamic splinting easier and faster. ... fit every splinting need. Non-slip foam ... the distal phalanx. One size is ... 10 and 25. FoamWrap™ splints are ...
Medicine Products: